Categories: NewsPharmaceutical

Avalyn to Participate in Multiple Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) — Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for life-threatening pulmonary diseases, today announced that management will participate in the following upcoming investor conferences in August.

Barclays Private Biotech Symposium
Format:     1×1 Meetings
Date:    Wednesday, August 7, 2024
Location:   Virtual
Participants:    Lyn Baranowski, CEO; Douglas Carlson, CFO, CBO
     
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase
Format:    Company Presentation
Date:   Wednesday, August 14, 2024
Time:   2:30 – 2:50 p.m. ET
Location:   InterContinental Boston, Boston, MA
Participants:   Lyn Baranowski, CEO; Melissa Rhodes, COO
     

About Avalyn Pharma
Avalyn is a biopharmaceutical company developing inhaled therapies for the treatment of rare respiratory diseases including pulmonary fibrosis and other interstitial lung diseases (ILD). Pulmonary fibrosis is characterized by scarring of lung tissue, decline in lung function, reduced exercise capacity and quality of life, and is associated with increased mortality. Currently approved therapeutic options slow pulmonary fibrosis progression but are associated with significant toxicities that restrict their use and dosing. Avalyn is developing a pipeline of new inhaled formulations of approved medicines designed to reduce systemic exposure and deliver medication to the site of disease. Avalyn’s pipeline is led by AP01, an optimized inhaled formulation of pirfenidone, which has been assessed in 150 individuals with different forms of pulmonary fibrosis and demonstrated clinical proof-of-concept with improved efficacy and safety over existing therapies. For more information, please visit avalynpharma.com and follow us on LinkedIn.

Contacts:
Monique Allaire
THRUST Strategic Communications
monique@thrustsc.com

Staff

Recent Posts

KORU Medical Systems, Inc. Announces 2024 Q2 Financial Results, a Record Quarter With 22% Revenue Growth; Raises Full Year 2024 Guidance

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading…

6 hours ago

Sonendo, Inc. Reports Second Quarter 2024 Financial Results and Raises Full Year Revenue Guidance

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Sonendo, Inc. (“Sonendo” or the “Company”) (OTCQX: SONX), a leading dental technology…

6 hours ago

Outset Medical Reports Second Quarter 2024 Financial Results

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology…

6 hours ago

Medexus Announces Strong Fiscal Q1 2025 Results

Fiscal Q1 2025 revenue of $27.3 million, net income of $2.0 million, operating income of…

6 hours ago